Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 17 of 17 for “"Apremilast"”.

  1. Comparison of the modes of action of Apremilast and Roflumilast

    … investigated for use as therapeutic agents. Apremilast, a small molecule inhibitor of PDE 4 is in development for chronic inflammatory disorders and has shown promise for the treatment of psoriasis, psoriatic arthritis as well as other inflammatory diseases. It has been found to be safe and …

    glasgow Download PDF for Comparison of the modes of action of Apremilast and Roflumilast (opens in a new tab)

  2. Development of an amorphous based novel sustained release system for apremilast

    As a small molecule PDE 4 inhibitor, apremilast has drawn much attention for multiple promising indications. However, apremilast is a poorly water-soluble drug and has multiple polymorphic forms. This study aims to develop a sustained-release (SR) amorphous solid dispersion (ASD) system for …

    temple Repository record for Development of an amorphous based novel sustained release system for apremilast (opens in a new tab)

  3. cAMP-abhängige Signalkomplexe bei Pemphigus vulgaris

    … Mit der Zulassung des Phosphodiesterasehemmers Apremilast steht mittlerweile ein klinisch zugelassenes Medikament zu Verfügung, das, neben den in der Zulassungsstudie beschriebenen Effekten auf das Immunsystem, auch den cAMP-Spiegel in Keratinozyten erhöht. Im Herzmuskel wurde von einer Stärkung …

    lmu-germany Repository record for cAMP-abhängige Signalkomplexe bei Pemphigus vulgaris (opens in a new tab)

  4. Μελέτη πολυμορφισμών ανοσορυθμιστικών κυτοκινών σε ασθενείς με ψωρίαση και άλλες δερματολογικές παθήσεις

    … associated with treatment response to apremilast and secukinumab and evaluate their predictive value in therapeutic outcomes. Specifically, this study aims to investigate the impact of genetic polymorphisms on psoriasis patients treated with apremilast or secukinumab while …

    greece Repository record for Μελέτη πολυμορφισμών ανοσορυθμιστικών κυτοκινών σε ασθενείς με ψωρίαση και άλλες δερματολογικές παθήσεις (opens in a new tab)

  5. Chemokine orchestration of leukocyte-skin interactions

    … in patients treated with the PDE4 inhibitor Apremilast. Strikingly, Apremilast treatment of neutrophils led to the abolishment of intracellular calcium fluxes, known to be related to reduced neutrophil migration. Further to this, we show that Apremilast treatment of mice with psoriasiform …

    whiterose Download PDF for Chemokine orchestration of leukocyte-skin interactions (opens in a new tab)

  6. Η επίδραση της θεραπείας με αναστολείς της ιντερλευκίνης 17 και ιντερλευκίνης 23 στην αθηρωματική νόσο σε ασθενείς με μέτρια ή σοβαρή ψωρίαση κατά πλάκας

    … IL-23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the …

    greece Repository record for Η επίδραση της θεραπείας με αναστολείς της ιντερλευκίνης 17 και ιντερλευκίνης 23 στην αθηρωματική νόσο σε ασθενείς με μέτρια ή σοβαρή ψωρίαση κατά πλάκας (opens in a new tab)

  7. Novel approaches for ungual and trans-ungual delivery of drugs

    … project was to investigate the penetrability of apremilast into and across the nail plate, folloby the preparation of a novel nail lacquer formulation to improve its ungual and trans-ungual permeation for the treatment of nail psoriasis. Dexpanthenol and salicylic acid were found to be the …

    mississippi Repository record for Novel approaches for ungual and trans-ungual delivery of drugs (opens in a new tab)

  8. Welches Medikament hat den schnellsten Wirkeintritt in der Behandlung von Psoriasis-Arthritis?

    … 5mg (2,20 [1,41-2,99]); nach > 4 Wochen: Apremilast, Ustekinumab. Für TOA-ACR50 lagen alle Ergebnisse bei > 4 Wochen. Bezogen auf TOA-PASI75, zeigten gepoolte Ergebnisse einen Wirkeintritt nach < 3 Wochen für Therapien mit Ixekizumab und nach 6,03 Wochen [3,76-8,29] für Adalimumab. …

    fu-berlin Repository record for Welches Medikament hat den schnellsten Wirkeintritt in der Behandlung von Psoriasis-Arthritis? (opens in a new tab)

  9. Exploring co-milling as a strategy to improve the dissolution of poorly water-soluble drugs

    … between low Tg (fenofibrate) and high Tg (apremilast) drugs. Apremilast, milled below its Tg, exhibited progressive amorphization and supersaturation during dissolution testing. A strong linear correlation between melting point depression and maximum drug concentration (cmax) in vitro (R2 > …

    cork Repository record for Exploring co-milling as a strategy to improve the dissolution of poorly water-soluble drugs (opens in a new tab)

  10. Photochemical 3D Printing of Bioresorbable Copolyesters for Applications in Transdermal Drug Delivery and Soft Tissue Repair

    … than intravenous administration. Separately, apremilast-loaded, detachable MAPs were fabricated for sustained transdermal treatment of psoriasis. Detachable needles were designed to remain embedded in the skin after application, allowing for long-term drug release. Hollow MAPs were also …

    duke Repository record for Photochemical 3D Printing of Bioresorbable Copolyesters for Applications in Transdermal Drug Delivery and Soft Tissue Repair (opens in a new tab)

  11. Χαρακτηριστικά και αλλαγές θεραπείας ασθενών με Ψωριασική Αρθρίτιδα σε ένα κοινό δερματολογικό-ρευματολογικό ιατρείο

    … και 10% στοχευμένους συνθετικούς παράγοντες( apremilast). Kατά την τελευταία εκτίμηση (μετά από μέση διάρκεια 15μηνών), μόνο 8% δεν λάμβανε καμία θεραπεία , 62% λάμβανε βιολογικούς παράγοντες, 46% μη-βιολογικούς παράγοντες και 10% στοχευμένους συνθετικούς παράγοντες. Σχετικά με την ενεργότητα …

    athens Repository record for Χαρακτηριστικά και αλλαγές θεραπείας ασθενών με Ψωριασική Αρθρίτιδα σε ένα κοινό δερματολογικό-ρευματολογικό ιατρείο (opens in a new tab)

  12. Wirksamkeit und Sicherheit von systemischer Psoriasis-Therapie bei viraler Hepatitis, Diabetes mellitus oder Niereninsuffizienz. Systematische Reviews

    … Studien unzureichend berichtet. In Studien zu Apremilast, Methotrexat (MTX) und TNF-Inhibitoren (TNFi) (geringe Patientenanzahl, unterschiedliche Studientypen mit hohem Verzerrungssrisiko) fanden sich keine Hinweise auf relevante Veränderungen von Nüchternglukose, HbA1c oder Insulinsensitivität …

    fu-berlin Repository record for Wirksamkeit und Sicherheit von systemischer Psoriasis-Therapie bei viraler Hepatitis, Diabetes mellitus oder Niereninsuffizienz. Systematische Reviews (opens in a new tab)

  13. Συσχέτιση δεικτών φλεγμονής με την εμφάνιση και την πορεία κατάθλιψης σε ψωριασικούς ασθενείς πριν και μετά τη χορήγηση συστηματικής αγωγής

    … probably related to the use of ciclosporin and apremilast. As a result, these drugs should be administered with caution to patients with psoriasis and depression. The evaluation of both CRP and ESR and their use to detect the presence of depression in patients with psoriasis can be an important …

    greece Repository record for Συσχέτιση δεικτών φλεγμονής με την εμφάνιση και την πορεία κατάθλιψης σε ψωριασικούς ασθενείς πριν και μετά τη χορήγηση συστηματικής αγωγής (opens in a new tab)

  14. Decifrando os mecanismos moleculares de teratogênese da talidomida : genética, embriologia e biologia de sistemas

    … no presente estudo. Ensaios de exposição com apremilast, análogo anti-inflamatório da talidomida, e diclofenaco foram realizados em embriões de galinha. Não foram encontradas anomalias nos embriões, porém alta taxa de letalidade foi visualizada em altas doses. Ainda em embriões de galinha, …

    brazil-ufrgs Repository record for Decifrando os mecanismos moleculares de teratogênese da talidomida : genética, embriologia e biologia de sistemas (opens in a new tab)